<!DOCTYPE html SYSTEM "about:legacy-compat">
<html xmlns:codify="https://code.dccouncil.us/schemas/codify" lang="en-US" class="no-js">
  <head>
    <meta charset="utf-8"/>
    <title>D.C. Law 24-315. Opioid Litigation Proceeds Amendment Act of 2022. | D.C. Law Library</title>
    <link rel="shortcut icon" href="/us/dc/_document/v2/images/favicons/favicon.ico"/>
    <!--Meta-->
    <meta http-equiv="X-UA-Compatible" content="IE=EDGE"/>
    <meta name="viewport" content="width=device-width, initial-scale=1"/>
    <meta name="format-detection" content="telephone=no"/>
    <meta name="HandheldFriendly" content="true"/>
    <meta itemprop="toc-json" content="/us/dc/council/laws/24-315/index.json"/>
    <meta itemprop="doc-type" content="document"/>
    <meta itemprop="ref-doc" content="D.C. Law 24-315"/>
    <!--OpenGraph-->
    <meta property="og:url" content="https://code.dccouncil.us/us/dc/council/laws/24-315"/>
    <meta property="og:type" content="article"/>
    <meta property="og:title" content="D.C. Law 24-315. Opioid Litigation Proceeds Amendment Act of 2022. | D.C. Law Library"/>
    <meta property="og:image" content="https://code.dccouncil.us/us/dc/_document/v2/images/og/og_image.png"/>
    <!--Progressive Web App-->
    <link rel="manifest" href="/manifest.json"/>
    <meta name="msapplication-config" content="/browserconfig.xml"/>
    <meta name="apple-mobile-web-app-capable" content="yes"/>
    <meta name="apple-mobile-web-app-status-bar-style" content="#000000"/>
    <meta name="apple-mobile-web-app-title" content="D.C. Law Library"/>
    <meta name="theme-color" content="#000000"/>
    <meta name="msapplication-navbutton-color" content="#000000"/>
    <meta name="apple-mobile-web-app-capable" content="yes"/>
    <meta name="mobile-web-app-capable" content="yes"/>
    <!--PWA icons-->
    <link rel="apple-touch-icon" sizes="180x180" href="/us/dc/_document/v2/images/favicons/apple-touch-icon.png"/>
    <link rel="apple-touch-icon-precomposed" sizes="60x60" href="/us/dc/_document/v2/images/favicons/apple-touch-icon-60x60-precomposed.png"/>
    <link rel="apple-touch-icon-precomposed" sizes="76x76" href="/us/dc/_document/v2/images/favicons/apple-touch-icon-76x76-precomposed.png"/>
    <link rel="apple-touch-icon-precomposed" sizes="152x152" href="/us/dc/_document/v2/images/favicons/apple-touch-icon-152x152-precomposed.png"/>
    <link rel="apple-touch-icon-precomposed" sizes="180x180" href="/us/dc/_document/v2/images/favicons/apple-touch-icon-180x180-precomposed.png"/>
    <link rel="mask-icon" href="/us/dc/_document/v2/images/favicons/safari-pinned-tab.svg" color="#000000"/>
    <link rel="icon" type="image/png" sizes="16x16" href="/us/dc/_document/v2/images/favicons/favicon-16x16.png"/>
    <link rel="icon" type="image/png" sizes="32x32" href="/us/dc/_document/v2/images/favicons/favicon-32x32.png"/>
    <link rel="icon" type="image/png" sizes="48x48" href="/us/dc/_document/v2/images/favicons/favicon-48x48.png"/>
    <!--Fonts-->
    <link href="/us/dc/_document/v2/biticons/biticons.css" type="text/css" rel="stylesheet"/>
    <link href="/us/dc/_document/v2/fonts/droid-serif/droid-serif.css" type="text/css" rel="stylesheet"/>
    <link href="/us/dc/_document/v2/fonts/open-sans/open-sans.css" type="text/css" rel="stylesheet"/>
    <!--Document CSS-->
    <link href="/us/dc/_document/v2/styles/responsive.min.css" type="text/css" rel="stylesheet" media="screen"/>
    <link href="/us/dc/_document/v2/styles/main.min.css" type="text/css" rel="stylesheet" media="screen"/>
    <link href="/us/dc/_document/v2/styles/print.min.css" type="text/css" rel="stylesheet" media="print"/>
    <link href="/_reader/styles/main.min.css" type="text/css" rel="stylesheet"/>
    <script src="/_reader/js/main.js"> </script>
    <!--Links to resources that need to be prefetched-->
  </head>
  <body>
    <div role="region" id="announcer" aria-live="polite" class="sr-only" aria-atomic="true" aria-label="Live messages">
      <p id="message"> </p>
    </div>
    <nav class="visually-hidden">
      <a href="#area__content" class="skip-link">Skip to main content</a>
    </nav>
    <div id="grid" class="ns__document__us-dc">
      <header id="section__header" class="ns__document__us-dc">
        <div id="section__header__inner" class="ns__document__us-dc">
          <div id="area__logo" class="ns__document__us-dc">
            <a href="/" class="logo" aria-label="Logo - Return to home page">
              <img src="/us/dc/_document/v2/images/logo/dc-seal-outline.png" srcset="/us/dc/_document/v2/images/logo/dc-seal-outline.png 1x, /us/dc/_document/v2/images/logo/dc-seal-outline@2x.png 2x" alt="Council of the District of Columbia logo"/>
            </a>
          </div>
          <div id="area__main_title" class="ns__document__us-dc">
            <img src="/us/dc/_document/v2/images/logo/dccouncil_typemark.svg" srcset="" alt="D.C. Law Library"/>
          </div>
        </div>
      </header>
      <div id="section__content" class="ns__document__us-dc">
        <div id="section__content__inner" class="ns__document__us-dc">
          <section id="area__breadcrumbs" class="ns__document__us-dc" role="region" aria-label="Breadcrumbs">
            <input type="checkbox" id="menu-trigger" class="menu-trigger" aria-label="Mobile menu toggler"/>
            <label for="menu-trigger">
              <span class="visually-hidden">Toggle mobile menu</span>
            </label>
            <nav role="navigation" aria-label="Breadcrumb navigation">
              <div class="h__ui">Navigation</div>
              <ul class="ancestors">
                <li data-search-path="library|D.C. Code" aria-hidden="true" data-search-heading="D.C. Code" data-search-default="true" class="hidden"/>
                <li data-search-path="library" data-search-heading="All Documents" class="no-indent">
                  <a href="/" title="D.C. Law Library">D.C. Law Library</a>
                </li>
                <li data-search-path="library|dclaws" data-search-heading="D.C. Laws" class="no-indent">
                  <a href="/dclaws" title="D.C. Laws Codified in the D.C. Code">D.C. Laws Codified in the D.C. Code</a>
                </li>
                <li data-search-path="library|dclaws|24" data-search-heading="" class="no-indent">
                  <a href="/dclaws/24" title="Council Period 24 (2021-2022)">Council Period 24 (2021-2022)</a>
                </li>
                <li data-search-path="library|dclaws|24|permanent" data-search-heading="" class="no-indent">
                  <a href="/dclaws/24/permanent" title="Permanent Laws">Permanent Laws</a>
                </li>
                <li data-search-path="library|dclaws|24|permanent|effective" data-search-heading="" class="no-indent">
                  <a href="/dclaws/24/permanent/effective" title="Laws">Laws</a>
                </li>
                <li data-search-path="library|dclaws|24|permanent|effective|D.C. Law 24-315" data-search-heading="" class="li__book-open">
                  <span title="D.C. Law 24-315. Opioid Litigation Proceeds Amendment Act of 2022.">D.C. Law 24-315. Opioid Litigation Proceeds Amendment Act of 2022.</span>
                </li>
              </ul>
            </nav>
          </section>
          <main id="area__content" class="ns__document__us-dc">
            <article class="content" role="document">
              <div class="tuf-authenticate">
                <h1 class="h__toc" id="/us/dc/council/laws/24-315">D.C. Law 24-315. Opioid Litigation Proceeds Amendment Act of 2022.</h1>
                <p class="text--center">AN ACT</p>
                <p class="text--italic">To establish an Opioid Abatement Advisory Commission to make recommendations to the Mayor and Council regarding the use of opioid litigation settlement proceeds and District-wide goals, objectives, and performance indicators relating to opioid use disorder and co-occurring substance use and mental health disorders, and to establish an Office of Opioid Abatement and set forth its powers and duties; to amend the Attorney General for the District of Columbia Clarification and Elected Term Amendment Act of 2010 to make conforming changes; and to amend the Opioid Abatement Fund Establishment Act of 2022 to clarify the monies to be deposited into the Opioid Abatement Fund, to provide for how monies in the Opioid Abatement Fund shall be spent, to require an annual report to the Mayor, Council, and Attorney General concerning opioid abatement activities and the use of monies deposited into the Opioid Abatement Fund, and to require an audit of the Opioid Abatement Fund.</p>
                <p>BE IT ENACTED BY THE COUNCIL OF THE DISTRICT OF COLUMBIA, That this act may be cited as the "Opioid Litigation Proceeds Amendment Act of 2022".</p>
                <aside class="marginalia" role="note">
                  <p>
                    <span class="text--bold">New <a class="no-wrap" href="/us/dc/council/code/titles/7/chapters/32/subchapters/II">subchapter II of Chapter 32 of Title 7</a></span>
                  </p>
                </aside>
                <h1>TITLE I. OPIOID ABATEMENT</h1>
                <aside class="marginalia" role="note">
                  <p>
                    <span class="text--bold">New <a class="no-wrap" href="/us/dc/council/code/sections/7-3211">§ 7-3211</a></span>
                  </p>
                </aside>
                <p id="&#xA7;101"><span class="level-num">Sec. 101. </span>Definitions.</p>
                <p class="text-indent-1"> For the purposes of <code-cite doc="D.C. Code" path="7|32|II">this title</code-cite>, the term:</p>
                <p class="text-indent-2"><span class="level-num" id="&#xA7;101(1)">(1)</span> "Commission" means the Opioid Abatement Advisory Commission established by <code-cite doc="D.C. Code" path="&#xA7;7-3212">section 102</code-cite>.</p>
                <p class="text-indent-2"><span class="level-num" id="&#xA7;101(2)">(2)</span> "Evidence-based" means that an activity, practice, program, service, support, or strategy has undergone multiple randomized controlled trials and observational studies demonstrating that it helps individuals avoid the development and progression of opioid and other substance use disorders or drug-related harms, reduces the adverse consequences of opioid and other substance use, or manages, slows the progression of, or supports recovery from an opioid use disorder or co-occurring substance use or mental health disorder.</p>
                <p class="text-indent-2"><span class="level-num" id="&#xA7;101(3)">(3)</span> "Evidence-informed" means an activity, practice, program, service, support, or strategy that incorporates the best available evidence, patient needs, values, and preferences, and practitioner expertise into the decision-making process.</p>
                <p class="text-indent-2"><span class="level-num" id="&#xA7;101(4)">(4)</span> "Fund" means the Opioid Abatement Fund established by <code-cite doc="D.C. Code" path="&#xA7;7-3221">section 5012 of the Opioid Abatement Fund Establishment Act of 2022, effective September 21, 2022 (D.C. Law 24-167; D.C. Official Code § 1-325.441)</code-cite>.</p>
                <p class="text-indent-2"><span class="level-num" id="&#xA7;101(5)">(5)</span> "Harm reduction" means an activity, practice, program, service, support, or strategy that addresses both conditions that precede and occur as a result of substance use and attempts to reduce the adverse consequences of opioid and other substance use among persons who continue to use those substances.</p>
                <p class="text-indent-2"><span class="level-num" id="&#xA7;101(6)">(6)</span> "Infrastructure" means the resources, such as personnel, buildings, or equipment, required for the District or another entity to provide evidence-based and evidence-informed harm reduction, prevention, recovery, and treatment activities, practices, programs, services, supports, and strategies to individuals with opioid use disorder and co-occurring substance use and mental health disorders.</p>
                <p class="text-indent-2"><span class="level-num" id="&#xA7;101(7)">(7)</span> "Office" means the Office of Opioid Abatement established by <code-cite doc="D.C. Code" path="&#xA7;7-3213">section 103</code-cite>.</p>
                <p class="text-indent-2"><span class="level-num" id="&#xA7;101(8)">(8)</span> "Prevention" means primary, secondary, and tertiary efforts to help individuals avoid the development and progression of opioid use disorder and co-occurring substance use and mental health disorders and drug-related harms.</p>
                <p class="text-indent-2"><span class="level-num" id="&#xA7;101(9)">(9)</span> "Recovery" means a process through which an individual develops a healthier life, which may include:</p>
                <p class="text-indent-3"><span class="level-num" id="&#xA7;101(9)(A)">(A)</span> Improving the individual's quality of life, including the individual's physical and mental health;</p>
                <p class="text-indent-3"><span class="level-num" id="&#xA7;101(9)(B)">(B)</span> The individual's consistent pursuit of abstinence from the substances or behaviors that have negatively impacted them, their family, and their community;</p>
                <p class="text-indent-3"><span class="level-num" id="&#xA7;101(9)(C)">(C)</span> Relief of the individual's symptoms, including substance craving; and</p>
                <p class="text-indent-3"><span class="level-num" id="&#xA7;101(9)(D)">(D)</span> Improvement of the individual's relationships, social connectedness, and interpersonal skills.</p>
                <p class="text-indent-2"><span class="level-num" id="&#xA7;101(10)">(10)</span> "Treatment" means:</p>
                <p class="text-indent-3"><span class="level-num" id="&#xA7;101(10)(A)">(A)</span> An evidence-based or evidence-informed activity, practice, program, service, support, or strategy to intervene upon, care for, manage, slow the progression of, or support recovery from opioid use disorder or co-occurring substance use or mental health disorders;</p>
                <p class="text-indent-3"><span class="level-num" id="&#xA7;101(10)(B)">(B)</span> That is individualized to address each individual's medical needs; and</p>
                <p class="text-indent-3"><span class="level-num" id="&#xA7;101(10)(C)">(C)</span> That includes screening for and diagnosis of substance use disorders or co-occurring mental or physical health disorders, as well as pharmacological and non-pharmacological therapeutic interventions for opioid use disorder or co-occurring substance use or mental health disorders.</p>
                <aside class="marginalia" role="note">
                  <p>
                    <span class="text--bold">New <a class="no-wrap" href="/us/dc/council/code/sections/7-3212">§ 7-3212</a></span>
                  </p>
                </aside>
                <p id="&#xA7;102"><span class="level-num">Sec. 102. </span>Opioid Abatement Advisory Commission.</p>
                <p class="text-indent-1"><span class="level-num" id="&#xA7;102(a)">(a)</span> There is established an Opioid Abatement Advisory Commission.</p>
                <p class="text-indent-1"><span class="level-num" id="&#xA7;102(b)">(b)</span> The purpose of the Commission shall be to:</p>
                <p class="text-indent-2"><span class="level-num" id="&#xA7;102(b)(1)">(1)</span> Ensure that the monies the District receives and deposits into the Fund are appropriately expended on evidence-based and evidence-informed harm reduction, prevention, recovery, and treatment activities, practices, programs, services, supports, and strategies for opioid use disorder and co-occurring substance use and mental health disorders;</p>
                <p class="text-indent-2"><span class="level-num" id="&#xA7;102(b)(2)">(2)</span> Prioritize and facilitate public involvement, accountability, and transparency in allocating and accounting for these monies; and</p>
                <p class="text-indent-2"><span class="level-num" id="&#xA7;102(b)(3)">(3)</span> Ensure that the monies the District receives and deposits into the Fund have the effect of preventing, treating, and reducing opioid use disorder and co-occurring substance use and mental health disorders and reducing fatalities.</p>
                <p class="text-indent-1"><span class="level-num" id="&#xA7;102(c)">(c)</span> The Commission shall be composed of 21 members, or the member's designee, as follows:</p>
                <p class="text-indent-2"><span class="level-num" id="&#xA7;102(c)(1)">(1)</span> The Director of the Department of Behavioral Health;</p>
                <p class="text-indent-2"><span class="level-num" id="&#xA7;102(c)(2)">(2)</span> The Director of the Department of Health;</p>
                <p class="text-indent-2"><span class="level-num" id="&#xA7;102(c)(3)">(3)</span> The Director of the Department of Health Care Finance;</p>
                <p class="text-indent-2"><span class="level-num" id="&#xA7;102(c)(4)">(4)</span> The Deputy Mayor for Health and Human Services;</p>
                <p class="text-indent-2"><span class="level-num" id="&#xA7;102(c)(5)">(5)</span> The Deputy Mayor for Public Safety and Justice;</p>
                <p class="text-indent-2"><span class="level-num" id="&#xA7;102(c)(6)">(6)</span> The Chief Medical Examiner;</p>
                <p class="text-indent-2"><span class="level-num" id="&#xA7;102(c)(7)">(7)</span> The Attorney General;</p>
                <p class="text-indent-2"><span class="level-num" id="&#xA7;102(c)(8)">(8)</span> The Chairperson of the Council committee with jurisdiction over health matters;</p>
                <p class="text-indent-2"><span class="level-num" id="&#xA7;102(c)(9)">(9)</span> Five members appointed by the Mayor, with the following qualifications:</p>
                <p class="text-indent-3"><span class="level-num" id="&#xA7;102(c)(9)(A)">(A)</span> One member with experience in providing prevention, recovery, treatment, or harm reduction services for opioid use disorder and co-occurring substance use and mental health disorders;</p>
                <p class="text-indent-3"><span class="level-num" id="&#xA7;102(c)(9)(B)">(B)</span> Two members, respectively, with professional expertise and educational backgrounds in:</p>
                <p class="text-indent-4"><span class="level-num" id="&#xA7;102(c)(9)(B)(i)">(i)</span> Medicine; and</p>
                <p class="text-indent-4"><span class="level-num" id="&#xA7;102(c)(9)(B)(ii)">(ii)</span> Mental health services;</p>
                <p class="text-indent-3"><span class="level-num" id="&#xA7;102(c)(9)(C)">(C)</span> One member who has experienced opioid use disorder and co-occurring substance use and mental health disorders and recovery; and</p>
                <p class="text-indent-3"><span class="level-num" id="&#xA7;102(c)(9)(D)">(D)</span> One family member of a person or decedent who experienced opioid use disorder and co-occurring substance use and mental health disorders;</p>
                <p class="text-indent-2"><span class="level-num" id="&#xA7;102(c)(10)">(10)</span> One representative each from the:</p>
                <p class="text-indent-3"><span class="level-num" id="&#xA7;102(c)(10)(A)">(A)</span> District of Columbia Behavioral Health Association;</p>
                <p class="text-indent-3"><span class="level-num" id="&#xA7;102(c)(10)(B)">(B)</span> Medical Society of the District of Columbia;</p>
                <p class="text-indent-3"><span class="level-num" id="&#xA7;102(c)(10)(C)">(C)</span> District of Columbia Primary Care Association; and</p>
                <p class="text-indent-3"><span class="level-num" id="&#xA7;102(c)(10)(D)">(D)</span> District of Columbia Hospital Association; and</p>
                <p class="text-indent-2"><span class="level-num" id="&#xA7;102(c)(11)">(11)</span> Four members appointed by the Chairman of the Council, with the following qualifications:</p>
                <p class="text-indent-3"><span class="level-num" id="&#xA7;102(c)(11)(A)">(A)</span> Two members with current experience as direct service providers of prevention, recovery, treatment, or harm reduction services for opioid use disorder and co-occurring substance use and mental health disorders;</p>
                <p class="text-indent-3"><span class="level-num" id="&#xA7;102(c)(11)(B)">(B)</span> One member with professional expertise and an educational background in public health policy or research; and</p>
                <p class="text-indent-3"><span class="level-num" id="&#xA7;102(c)(11)(C)">(C)</span> One member who has experienced opioid use disorder and co-occurring substance use and mental health disorders and recovery.</p>
                <p class="text-indent-1"><span class="level-num" id="&#xA7;102(d)">(d)</span> The Commission shall elect a Chair from among its members.</p>
                <p class="text-indent-1"><span class="level-num" id="&#xA7;102(e)">(e)</span><span class="level-num" id="&#xA7;102(e)(1)">(1)</span> Each member appointed pursuant to subsection (c)(9) and (11) of this section shall serve a 3-year term; except, that:</p>
                <p class="text-indent-3"><span class="level-num" id="&#xA7;102(e)(1)(A)">(A)</span> Of the Mayor's initial appointments, 2 members shall be appointed for terms of one year, and 2 members shall be appointed for terms of 2 years; and</p>
                <p class="text-indent-3"><span class="level-num" id="&#xA7;102(e)(1)(B)">(B)</span> Of the Council's initial appointments, one member shall be appointed for a term of one year, and 2 members shall be appointed for terms of 2 years.</p>
                <p class="text-indent-2"><span class="level-num" id="&#xA7;102(e)(2)">(2)</span> Members shall serve:</p>
                <p class="text-indent-3"><span class="level-num" id="&#xA7;102(e)(2)(A)">(A)</span> Following the expiration of their terms until their successors have been appointed;</p>
                <p class="text-indent-3"><span class="level-num" id="&#xA7;102(e)(2)(B)">(B)</span> For a maximum of 2 full terms, with partial term service not counted toward this maximum; and</p>
                <p class="text-indent-3"><span class="level-num" id="&#xA7;102(e)(2)(C)">(C)</span> Without compensation; provided, that they shall be reimbursed for necessary expenses incurred in carrying out Commission duties.</p>
                <p class="text-indent-2"><span class="level-num" id="&#xA7;102(e)(3)">(3)</span> Vacancies shall be filled in the same manner as the original appointment for the remainder of the term.</p>
                <p class="text-indent-1"><span class="level-num" id="&#xA7;102(f)">(f)</span> The Commission shall hold public meetings at least quarterly, with meetings called by the Chair or a majority of Commission members. All Commission meetings shall be subject to <code-cite doc="D.C. Code" path="2|5|IV">the Open Meetings Act, effective March 31, 2011 (D.C. Law 18-350; D.C. Official Code § 2-571 <em>et seq.</em>)</code-cite>.</p>
                <p class="text-indent-1"><span class="level-num" id="&#xA7;102(g)">(g)</span> A majority of the Commission's members shall constitute a quorum, and actions of the Commission shall be taken by an affirmative vote of a majority of the members in attendance at a meeting where a quorum is present. Members may attend in person or remotely through audio or audiovisual means.</p>
                <p class="text-indent-1"><span class="level-num" id="&#xA7;102(h)">(h)</span> The Commission shall have the power and duty to:</p>
                <p class="text-indent-2"><span class="level-num" id="&#xA7;102(h)(1)">(1)</span> Establish procedures for the Commission's operations; and</p>
                <p class="text-indent-2"><span class="level-num" id="&#xA7;102(h)(2)">(2)</span> Make recommendations to the Mayor and Council regarding:</p>
                <p class="text-indent-3"><span class="level-num" id="&#xA7;102(h)(2)(A)">(A)</span> District-wide goals, objectives, and performance indicators relating to:</p>
                <p class="text-indent-4"><span class="level-num" id="&#xA7;102(h)(2)(A)(i)">(i)</span> Prevention, recovery, treatment, and harm reduction infrastructure, activities, practices, programs, services, supports, and strategies for opioid use disorder and co-occurring substance use and mental health disorders;</p>
                <p class="text-indent-4"><span class="level-num" id="&#xA7;102(h)(2)(A)(ii)">(ii)</span> Reducing disparities in access to prevention, recovery, treatment, and harm reduction infrastructure, activities, practices, programs, services, supports, and strategies; and</p>
                <p class="text-indent-4"><span class="level-num" id="&#xA7;102(h)(2)(A)(iii)">(iii)</span> Improving outcomes and reducing mortality in traditionally underserved populations, including for communities of color and current or formerly incarcerated individuals, with regard to prevention, recovery, treatment, and harm reduction infrastructure, activities, practices, programs, services, supports, and strategies;</p>
                <p class="text-indent-3"><span class="level-num" id="&#xA7;102(h)(2)(B)">(B)</span> Governing principles, policies, and procedures for the application for and awarding of monies and grants from the Fund;</p>
                <p class="text-indent-3"><span class="level-num" id="&#xA7;102(h)(2)(C)">(C)</span> Awards of monies and grants from the Fund;</p>
                <p class="text-indent-3"><span class="level-num" id="&#xA7;102(h)(2)(D)">(D)</span> The performance and outcomes of Fund awardees and grantees;</p>
                <p class="text-indent-3"><span class="level-num" id="&#xA7;102(h)(2)(E)">(E)</span> Management of the Fund; and</p>
                <p class="text-indent-3"><span class="level-num" id="&#xA7;102(h)(2)(F)">(F)</span> Any changes to the Fund's purposes.</p>
                <p class="text-indent-1"><span class="level-num" id="&#xA7;102(i)">(i)</span> The Commission's recommendations for the awarding of monies and grants pursuant to subsection (h)(2)(C) of this section shall include the consideration of:</p>
                <p class="text-indent-2"><span class="level-num" id="&#xA7;102(i)(1)">(1)</span> The number of individuals, per capita, with an opioid use disorder, and the number of overdose deaths per capita, in the area that a prospective awardee or grantee seeks to serve;</p>
                <p class="text-indent-2"><span class="level-num" id="&#xA7;102(i)(2)">(2)</span> Disparities in access to care and health outcomes in the area that a prospective awardee or grantee seeks to serve; and</p>
                <p class="text-indent-2"><span class="level-num" id="&#xA7;102(i)(3)">(3)</span> The infrastructure, activities, practices, programs, services, supports, and strategies currently available to individuals with an opioid use disorder in an area that a prospective awardee or grantee seeks to serve.</p>
                <aside class="marginalia" role="note">
                  <p>
                    <span class="text--bold">New <a class="no-wrap" href="/us/dc/council/code/sections/7-3213">§ 7-3213</a></span>
                  </p>
                </aside>
                <p id="&#xA7;103"><span class="level-num">Sec. 103. </span>Office of Opioid Abatement.</p>
                <p class="text-indent-1"><span class="level-num" id="&#xA7;103(a)">(a)</span><span class="level-num" id="&#xA7;103(a)(1)">(1)</span> There is established within the Department of Behavioral Health the Office of Opioid Abatement.</p>
                <p class="text-indent-2"><span class="level-num" id="&#xA7;103(a)(2)">(2)</span> The Office shall be led by a Director with at least 10 years' professional experience and education in prevention, recovery, treatment, and harm reduction efforts for opioid use disorder and co-occurring substance use and mental health disorders.</p>
                <p class="text-indent-1"><span class="level-num" id="&#xA7;103(b)">(b)</span> The Office shall have the power and duty to:</p>
                <p class="text-indent-2"><span class="level-num" id="&#xA7;103(b)(1)">(1)</span> Conduct a District-wide needs assessment to identify structural gaps and needs related to opioid use disorder and co-occurring substance use and mental health disorders;</p>
                <p class="text-indent-2"><span class="level-num" id="&#xA7;103(b)(2)">(2)</span> Support the Commission's activities by providing staffing, research and policy expertise, facilities, technical assistance, and other resources;</p>
                <p class="text-indent-2"><span class="level-num" id="&#xA7;103(b)(3)">(3)</span> Assist the Commission in preparing its recommendations regarding goals, objectives, and performance indicators pursuant to <code-cite doc="D.C. Code" path="&#xA7;7-3212|(h)|(2)|(A)">section 102(h)(2)(A)</code-cite>;</p>
                <p class="text-indent-2"><span class="level-num" id="&#xA7;103(b)(4)">(4)</span> Integrate the work of the Office and Commission and Fund expenditures with existing District strategic planning related to opioid use disorder and co-occurring substance use and mental health disorders;</p>
                <p class="text-indent-2"><span class="level-num" id="&#xA7;103(b)(5)">(5)</span> Develop governing principles, policies, and procedures for the application and awarding of monies and grants from the Fund;</p>
                <p class="text-indent-2"><span class="level-num" id="&#xA7;103(b)(6)">(6)</span> Oversee expenditures from the Fund, including by preparing a quarterly accounting of expenditures from the Fund and the Fund balance;</p>
                <p class="text-indent-2"><span class="level-num" id="&#xA7;103(b)(7)">(7)</span> Issue, manage, and oversee awards and grants from the Fund, including collecting and publicly reporting data from awardees and grantees concerning the effectiveness of infrastructure, activities, practices, programs, services, supports, and strategies funded;</p>
                <p class="text-indent-2"><span class="level-num" id="&#xA7;103(b)(8)">(8)</span> Prepare the annual report required by <code-cite doc="D.C. Code" path="&#xA7;7-3221|(f)">section 5012(f) of the Opioid Abatement Fund Establishment Act of 2022, effective September 21, 2022 (D.C. Law 24-167; D.C. Official Code § 1-325.441(f))</code-cite>; and</p>
                <p class="text-indent-2"><span class="level-num" id="&#xA7;103(b)(9)">(9)</span> Create and maintain a public website that includes:</p>
                <p class="text-indent-3"><span class="level-num" id="&#xA7;103(b)(9)(A)">(A)</span> Commission meeting attendance, agendas, and minutes;</p>
                <p class="text-indent-3"><span class="level-num" id="&#xA7;103(b)(9)(B)">(B)</span> The governing principles, policies, and procedures developed pursuant to paragraph (5) of this subsection;</p>
                <p class="text-indent-3"><span class="level-num" id="&#xA7;103(b)(9)(C)">(C)</span> The quarterly accountings of Fund expenditures and Fund balance prepared pursuant to paragraph (6) of this subsection;</p>
                <p class="text-indent-3"><span class="level-num" id="&#xA7;103(b)(9)(D)">(D)</span> A listing of awards and grants from the Fund and awardee and grantee data collected pursuant to paragraph (7) of this subsection; and</p>
                <p class="text-indent-3"><span class="level-num" id="&#xA7;103(b)(9)(E)">(E)</span> The annual reports prepared pursuant to<code-cite doc="D.C. Code" path="&#xA7;7-3221|(f)"> section 5012(f) of the Opioid Abatement Fund Establishment Act of 2022, effective September 21, 2022 (D.C. Law 24-167; D.C. Official Code § 1-325.441(f))</code-cite>.</p>
                <p class="text-indent-1"><span class="level-num" id="&#xA7;103(c)">(c)</span><span class="level-num" id="&#xA7;103(c)(1)">(1)</span> If the Office decides not to follow a Commission recommendation in whole or in part, the Office shall provide the Commission with a written explanation for its decision within 14 days after the decision is made.</p>
                <p class="text-indent-2"><span class="level-num" id="&#xA7;103(c)(2)">(2)</span> The Commission shall have at least 7 days after receipt of the Office's written explanation provided pursuant to paragraph (1) of this subsection to provide a written response before the Office proceeds with its decision.</p>
                <aside class="marginalia" role="note">
                  <p>
                    <span class="text--bold">New <a class="no-wrap" href="/us/dc/council/code/sections/7-3214">§ 7-3214</a></span>
                  </p>
                </aside>
                <p id="&#xA7;104"><span class="level-num">Sec. 104. </span>Rules.</p>
                <p>The Mayor, pursuant to <code-cite doc="D.C. Code" path="2|5|I">Title I of the District of Columbia Administrative Procedure Act, approved October 21, 1968 (82 Stat. 1204; D.C. Official Code 2-501 <em>et seq.</em>)</code-cite>, may issue rules to implement the provisions of <code-cite doc="D.C. Code" path="7|32|II">this title</code-cite>.</p>
                <aside class="marginalia" role="note">
                  <p>
                    <span class="text--bold">New <a class="no-wrap" href="/us/dc/council/code/titles/7/chapters/32/subchapters/III">subchapter III of Chapter 32 of Title 7</a></span>
                  </p>
                </aside>
                <h1>TITLE II. AMENDMENTS</h1>
                <p id="&#xA7;201"><span class="level-num">Sec. 201. </span>Section 106b of the Attorney General for the District of Columbia Clarification and Elected Term Amendment Act of 2010, effective October 22, 2015 (D.C. Law 21-36; D.C. Official Code § 1-301.86b), is amended as follows:</p>
                <aside class="marginalia" role="note">
                  <p>
                    <span class="text--bold">Amend <a class="no-wrap" href="/us/dc/council/code/sections/1-301.86b">§ 1-301.86b</a></span>
                  </p>
                </aside>
                <p class="text-indent-1"><span class="level-num" id="&#xA7;201(a)">(a)</span> Subsection (b) is amended as follows:</p>
                <p class="text-indent-2"><span class="level-num" id="&#xA7;201(a)(1)">(1)</span> Paragraph (2) is amended by striking the phrase "; and" and inserting a semicolon in its place.</p>
                <p class="text-indent-2"><span class="level-num" id="&#xA7;201(a)(2)">(2)</span> Paragraph (3) is amended by striking the period and inserting the phrase "; and" in its place.</p>
                <p class="text-indent-2"><span class="level-num" id="&#xA7;201(a)(3)">(3)</span> A new paragraph (4) is added to read as follows:</p>
                <p class="text-indent-2 quote">"<span class="level-num">(4)</span> Subject to the limitations of subsection (d)(3)(D) of this section, funds received pursuant to <code-cite doc="D.C. Code" path="&#xA7;7-3221|(b)|(1)">section 5012(b)(1)</code-cite> and <cite doc="D.C. Code" path="&#xA7;7-3221|(b)|(1A)">(1A)</cite><span codify:value=""> of the Opioid Abatement Fund Establishment Act of 2022, effective September 21, 2022 (D.C. Law 24-167; D.C. Official Code § 1-325.441(b)(1), (1A))</span>.".</p>
                <aside class="marginalia" role="note">
                  <p>
                    <span class="text--bold">Amend <a class="no-wrap" href="/us/dc/council/code/sections/1-301.86b">§ 1-301.86b</a></span>
                  </p>
                </aside>
                <p class="text-indent-1"><span class="level-num" id="&#xA7;201(b)">(b)</span> Subsection (d)(3)(D) is amended to read as follows:</p>
                <p class="text-indent-3 quote">"<span class="level-num">(D)</span> The Attorney General shall transfer to the Opioid Abatement Fund, established by <code-cite doc="D.C. Code" path="&#xA7;7-3221">section 5012 of the Opioid Abatement Fund Establishment Act of 2022, effective September 21, 2022 (D.C. Law 24-167; D.C. Official Code § 1-325.441)</code-cite>, at least 85% of any payment received prior to October 1, 2022, in settlement of the cases and settlements, judgments, and consent decrees specified in <code-cite doc="D.C. Code" path="&#xA7;7-3221|(b)|(1)">section 5012(b)(1)</code-cite> and <cite doc="D.C. Code" path="&#xA7;7-3221|(b)|(1A)">(1A)</cite><span codify:value=""> of the Opioid Abatement Fund Establishment Act of 2022, effective September 21, 2022 (D.C. Law 24-167; D.C. Official Code § 1-325.441(b)(1) and (1A))</span>, that was deposited into the Fund, and at least 90% of any payment received thereafter. The Attorney General may elect to retain the remainder of each such payment in the Fund by providing the Mayor, Chief Financial Officer, and Council with written notice of the amount of the election and the relevant payment. In making this election, the Attorney General shall ensure compliance with all applicable settlement terms.".</p>
                <p id="&#xA7;202"><span class="level-num">Sec. 202. </span>Section 5012 of the Opioid Abatement Fund Establishment Act of 2022, effective September 21, 2022 (D.C. Law 24-167; D.C. Official Code § 1-325.441), is amended as follows:</p>
                <aside class="marginalia" role="note">
                  <p>
                    <span class="text--bold">Amend <a class="no-wrap" href="/us/dc/council/code/sections/7-3221">§ 7-3221</a></span>
                  </p>
                </aside>
                <p class="text-indent-1"><span class="level-num" id="&#xA7;202(a)">(a)</span> Subsection (a) is amended by striking the phrase "the Mayor" and inserting the phrase "the Department of Behavioral Health" in its place.</p>
                <aside class="marginalia" role="note">
                  <p>
                    <span class="text--bold">Amend <a class="no-wrap" href="/us/dc/council/code/sections/7-3221">§ 7-3221</a></span>
                  </p>
                </aside>
                <p class="text-indent-1"><span class="level-num" id="&#xA7;202(b)">(b)</span> Subsection (b) is amended as follows:</p>
                <p class="text-indent-2"><span class="level-num" id="&#xA7;202(b)(1)">(1)</span> Paragraph (1) is amended as follows:</p>
                <p class="text-indent-3"><span class="level-num" id="&#xA7;202(b)(1)(A)">(A)</span> The lead-in language is amended by striking the phrase "time, in settlement of D.C. Superior Court cases" and inserting the phrase "time, pursuant to the settlement and trust-distribution agreements entered in the following cases" in its place.</p>
                <p class="text-indent-3"><span class="level-num" id="&#xA7;202(b)(1)(B)">(B)</span> Subparagraph (A) is amended by striking the phrase "Case No. 2022-CA-001441-B" and inserting the phrase "Case No. 2022-CA-001441-B (D.C. Super. Ct.)" in its place.</p>
                <p class="text-indent-3"><span class="level-num" id="&#xA7;202(b)(1)(C)">(C)</span> Subparagraph (B) is amended to read as follows:</p>
                <p class="text-indent-3 quote">"<span class="level-num">(B)</span> <em>District of Columbia v. McKesson Corp.,</em>, <em> et al.</em>, Case No. 2022-CA-001401-B (D.C. Super. Ct.);".</p>
                <p class="text-indent-3"><span class="level-num" id="&#xA7;202(b)(1)(D)">(D)</span> Subparagraph (C) is amended by striking the phrase "Case No. 2021-CA-00327-B; and" and inserting the phrase "Case No. 2021-CA-00327-B (D.C. Super. Ct.); and" in its place.</p>
                <p class="text-indent-3"><span class="level-num" id="&#xA7;202(b)(1)(E)">(E)</span> A new subparagraph (D) is added to read as follows:</p>
                <p class="text-indent-3 quote">"<span class="level-num">(D)</span> <em>In re Mallinckrodt PLC, No. 20-BK-12522 (Bankr. D. Del.)</em>;"</p>
                <p class="text-indent-2"><span class="level-num" id="&#xA7;202(b)(2)">(2)</span> A new paragraph (1A) is added to read as follows:</p>
                <p class="text-indent-2 quote">"<span class="level-num">(1A)</span> Funds received by the District pursuant to any pre- or post-suit settlement, judgment, or consent decree that the Attorney General designates as an opioid-related settlement, judgment, or consent decree; provided, that the Attorney General shall notify the Mayor and Council of any such designation within 30 days after the settlement, judgment, or consent decree becoming final; and".</p>
                <aside class="marginalia" role="note">
                  <p>
                    <span class="text--bold">Amend <a class="no-wrap" href="/us/dc/council/code/sections/7-3221">§ 7-3221</a></span>
                  </p>
                </aside>
                <p class="text-indent-1"><span class="level-num" id="&#xA7;202(c)">(c)</span> New subsections (b-1), (b-2), (b-3), and (b-4) are added to read as follows:</p>
                <p class="text-indent-1 quote">"<span class="level-num">(b-1)</span> Monies in the Fund shall be used only for the following purposes:</p>
                <p class="text-indent-2 quote">"<span class="level-num">(1)</span> Permissible Opioid Abatement Advisory Commission and Office of Opioid Abatement activities and operations, including personnel, pursuant to <span codify:value="&#xA7;&#xA7;">sections</span><code-cite doc="D.C. Code" path="&#xA7;7-3211" codify:value="7-3211">102</code-cite> and <code-cite doc="D.C. Code" path="&#xA7;7-3212" codify:value="7-3212">103 of the Opioid Litigation Proceeds Amendment Act of 2022, passed on 2nd reading on December 20, 2022 (Enrolled version of Bill 24-952)</code-cite>, respectively;</p>
                <p class="text-indent-2 quote">"<span class="level-num">(2)</span> District-wide needs assessments to identify structural gaps and needs related to opioid use disorder and co-occurring substance use and mental health disorders;</p>
                <p class="text-indent-2 quote">"<span class="level-num">(3)</span> Awards and grants for evidence-based and evidence-informed prevention, recovery, treatment, or harm reduction activities, practices, programs, services, supports, and strategies for opioid use disorder and co-occurring substance use and mental health disorders, including evidence-informed pilot programs or demonstration studies;</p>
                <p class="text-indent-2 quote">"<span class="level-num">(4)</span> Infrastructure required for evidence-based and evidence-informed prevention, recovery, treatment, or harm reduction activities, practices, programs, services, supports, and strategies for opioid use disorder and co-occurring substance use and mental health disorders;</p>
                <p class="text-indent-2 quote">"<span class="level-num">(5)</span> Evaluations of effectiveness and outcomes for activities, practices, programs, services, supports, and strategies for opioid use disorder and co-occurring substance use and mental health disorders for which monies from the Fund were disbursed, such as the impact on access to harm reduction, services, or treatment for disorders, or reduction in drug-related mortality;</p>
                <p class="text-indent-2 quote">"<span class="level-num">(6)</span> Publicly available data interfaces, including to aggregate, track, and report:</p>
                <p class="text-indent-3 quote">"<span class="level-num">(A)</span> Data on opioid use disorder and co-occurring substance use and mental health disorders, overdoses, and drug-related harms; and</p>
                <p class="text-indent-3 quote">"<span class="level-num">(B)</span> Outcomes of activities, practices, programs, services, supports, and strategies for which monies from the Fund were disbursed;</p>
                <p class="text-indent-2 quote">"<span class="level-num">(7)</span> The audit required by subsection (g) of this section; and</p>
                <p class="text-indent-2 quote">"<span class="level-num">(8)</span> Any other opioid abatement activities authorized by any settlement, judgment, or consent decree resulting in funds being deposited into the Fund.</p>
                <p class="text-indent-1 quote">"<span class="level-num">(b-2)</span> Unless otherwise required by court order, monies in the Fund shall be used for prospective purposes and not to reimburse expenditures incurred prior to <span codify:value="March 10, 2023">the effective date of the Opioid Litigation Proceeds Amendment Act of 2022, passed on 2nd reading on December 20, 2022 (Enrolled version of Bill 24-952)</span>.</p>
                <p class="text-indent-1 quote">"<span class="level-num">(b-3)</span> Monies expended from the Fund for the purposes set forth in subsection (b-1) of this section shall supplement, and not supplant, any other funds, including insurance benefits or District or federal funding, that would otherwise have been expended for such purposes.</p>
                <p class="text-indent-1 quote">"<span class="level-num">(b-4)</span> Expenditures for Commission and Office activities and operations, including personnel, and expenditures for audits shall comply with any applicable terms in the settlement agreements, judgments, or consent decrees that limit the use of funds for administrative expenses.".</p>
                <aside class="marginalia" role="note">
                  <p>
                    <span class="text--bold">Amend <a class="no-wrap" href="/us/dc/council/code/sections/7-3221">§ 7-3221</a></span>
                  </p>
                </aside>
                <p class="text-indent-1"><span class="level-num" id="&#xA7;202(d)">(d)</span> Subsection (c) is amended by striking the phrase "the Council of the District of Columbia" and inserting the phrase "the Council" in its place.</p>
                <aside class="marginalia" role="note">
                  <p>
                    <span class="text--bold">Amend <a class="no-wrap" href="/us/dc/council/code/sections/7-3221">§ 7-3221</a></span>
                  </p>
                </aside>
                <p class="text-indent-1"><span class="level-num" id="&#xA7;202(e)">(e)</span> New subsections (e), (f), and (g) are added to read as follows:</p>
                <p class="text-indent-1 quote">"<span class="level-num">(e)</span><span class="level-num">(1)</span> Notwithstanding subsection (b)(1) and (1A) of this section, the Attorney General may elect to have no more than 15% of any payment that the District receives prior to October 1, 2022, pursuant to the settlements, judgments, and consent decrees referenced in subsection (b)(1) and (1A) of this section, retained in the Litigation Support Fund established pursuant to <code-cite doc="D.C. Code" path="&#xA7;1-301.86b">section 106b of the Attorney General for the District of Columbia Clarification and Elected Term Amendment Act of 2010, effective October 22, 2015 (D.C. Law 21-36; D.C. Official Code § 1-301.86b)</code-cite>, and no more than 10% of any payment received thereafter.</p>
                <p class="text-indent-2 quote">"<span class="level-num">(2)</span> The Attorney General shall make an election pursuant to paragraph (1) of this subsection by providing the Mayor, Chief Financial Officer, and Council with written notice of the amount of the election and the relevant payment. In making this election, the Attorney General shall ensure compliance with all applicable settlement terms.</p>
                <p class="text-indent-1 quote">"<span class="level-num">(f)</span><span class="level-num">(1)</span> No later than December 31 of each year, the Department of Behavioral Health shall provide a report to the Mayor, Council, and Attorney General detailing the District's use of monies in the Fund during the prior fiscal year.</p>
                <p class="text-indent-2 quote">"<span class="level-num">(2)</span> The annual report required by paragraph (1) of this subsection shall:</p>
                <p class="text-indent-3 quote">"<span class="level-num">(A)</span> Be published on the Office of Opioid Abatement's website; and</p>
                <p class="text-indent-3 quote">"<span class="level-num">(B)</span> Include, for the prior fiscal year:</p>
                <p class="text-indent-4 quote">"<span class="level-num">(i)</span> The opening and closing balance of the Fund;</p>
                <p class="text-indent-4 quote">"<span class="level-num">(ii)</span> An accounting and description of all credits to and expenditures from the Fund;</p>
                <p class="text-indent-4 quote">"<span class="level-num">(iii)</span> An inventory of Fund investments, as of September 30 of the prior fiscal year;</p>
                <p class="text-indent-4 quote">"<span class="level-num">(iv)</span> The net income the Fund earned;</p>
                <p class="text-indent-4 quote">"<span class="level-num">(v)</span> A listing of all applications received for awards and grants of monies from the Fund;</p>
                <p class="text-indent-4 quote">"<span class="level-num">(vi)</span> The name and a description of each awardee or grantee of monies from the Fund, and the amount disbursed to each awardee or grantee;</p>
                <p class="text-indent-4 quote">"<span class="level-num">(vii)</span> A description of the intended use of each award or grant from the Fund, including the activity, practice, program, service, support, or strategy funded, population served, and measures that the awardee or grantee will use to assess the impact of the award;</p>
                <p class="text-indent-4 quote">"<span class="level-num">(viii)</span> The primary criteria used to select each awardee or grantee and its respective award or grant amount;</p>
                <p class="text-indent-4 quote">"<span class="level-num">(ix)</span> A statement as to whether monies disbursed from the Fund supplemented and did not supplant or replace any existing or future local, state, or federal government funding; and</p>
                <p class="text-indent-4 quote">"<span class="level-num">(x)</span> The progress toward achieving the Opioid Abatement Advisory Commission, Office of Opioid Abatement, and Fund's purposes, such as metrics on improving outcomes and reducing mortality and other harms related to opioid use disorder and co-occurring substance use and mental health disorders.</p>
                <p class="text-indent-1 quote">"<span class="level-num">(g)</span> The Office of the District of Columbia Auditor shall audit the Fund every 5 years.".</p>
                <h1>TITLE III. GENERAL PROVISIONS</h1>
                <p id="&#xA7;301"><span class="level-num">Sec. 301. </span>Applicability.</p>
                <p class="text-indent-1"><span class="level-num" id="&#xA7;301(a)">(a)</span> This act shall apply upon the date of inclusion of its fiscal effect in an approved budget and financial plan.</p>
                <p class="text-indent-1"><span class="level-num" id="&#xA7;301(b)">(b)</span> The Chief Financial Officer shall certify the date of the inclusion of the fiscal effect in an approved budget and financial plan, and provide notice to the Budget Director of the Council of the certification.</p>
                <p class="text-indent-1"><span class="level-num" id="&#xA7;301(c)">(c)</span><span class="level-num" id="&#xA7;301(c)(1)">(1)</span> The Budget Director shall cause the notice of the certification to be published in the District of Columbia Register.</p>
                <p class="text-indent-2"><span class="level-num" id="&#xA7;301(c)(2)">(2)</span> The date of publication of the notice of the certification shall not affect the applicability of this act.</p>
                <p id="&#xA7;302"><span class="level-num">Sec. 302. </span>Fiscal impact statement.</p>
                <p>The Council adopts the fiscal impact statement in the committee report as the fiscal impact statement required by section 4a of the General Legislative Procedures Act of 1975, approved October 16, 2006 (120 Stat. 2038; D.C. Official Code § 1-301.47a).</p>
                <p id="&#xA7;303"><span class="level-num">Sec. 303. </span>Effective date.</p>
                <p>This act shall take effect following approval by the Mayor (or in the event of veto by the Mayor, action by the Council to override the veto), a 30-day period of congressional review as provided in section 602(c)(1) of the District of Columbia Home Rule Act, approved December 24, 1973 (87 Stat. 813; D.C. Official Code § 1-206.02(c)(1)), and publication in the District of Columbia Register.</p>
              </div>
            </article>
          </main>
          <section id="area__document_meta" class="ui ns__document__us-dc">
            <h2 class="h__ui">Law Information</h2>
            <section>
              <h3 class="h__ui--small">Cites</h3>
              <ul>
                <li>D.C. Law 24-315 (<a class="internal-link" href="https://lims.dccouncil.gov/downloads/LIMS/51068/Signed_Act/B24-0952-Signed_Act.pdf">PDF</a>)</li>
                <li>D.C. Act 24-760 (<a class="internal-link" href="https://lims.dccouncil.gov/downloads/LIMS/51068/Signed_Act/B24-0952-Signed_Act.pdf">PDF</a>)</li>
                <li>70 DCR 838</li>
              </ul>
            </section>
            <section>
              <h3 class="h__ui--small">Effective</h3>
              <p>Mar. 10, 2023</p>
              <h3 class="h__ui--small">Legislative History (<a href="https://lims.dccouncil.us/Legislation/B24-0952">LIMS</a>)</h3>
              <p>Law 24-315, the “Opioid Litigation Proceeds Amendment Act of 2022,” was introduced in the Council and assigned Bill No. 24-952 which was referred to the Judiciary and Public Safety. The bill was adopted on first and second readings on Dec. 6, 2022, and Dec. 20, 2022, respectively. After mayoral review, it was assigned Act No. 24-760 on Jan. 17, 2023, and transmitted to Congress for its review. D.C. Law 24-315 became effective Mar. 10, 2023.</p>
            </section>
          </section>
        </div>
      </div>
      <footer id="section__footer" class="ns__document__us-dc">
        <div id="section__footer__inner" class="ns__document__us-dc">
          <section id="area__footer__logo" class="ns__document__us-dc">
            <a href="/" class="logo" aria-label="Logo - Return to home page">
              <img src="/us/dc/_document/v2/images/logo/dc-seal.png" srcset="/us/dc/_document/v2/images/logo/dc-seal.png 1x, /us/dc/_document/v2/images/logo/dc-seal@2x.png 2x" alt="Council of the District of Columbia logo"/>
            </a>
          </section>
          <div id="area__footer__content" class="ns__document__us-dc">
            <p>The codes and laws on this website are in the public domain.</p>
            <p>
      Please do not scrape. Instead, bulk download the <a href="https://github.com/dccouncil/law-html">HTML</a> or <a href="https://github.com/dccouncil/law-xml">XML</a>.
    </p>
            <p>Powered by the non-profit <a href="http://www.openlawlib.org/">Open Law Library</a>.</p>
          </div>
        </div>
      </footer>
    </div>
    <!--Piwik analytics-->
    <noscript>
      <img src="/_analytics/pixel.png" style="border:0;" alt=""/>
    </noscript>
  </body>
</html>
